Status:
ENROLLING_BY_INVITATION
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
Lead Sponsor:
Qbtech AB
Conditions:
Attention Deficit Disorder With Hyperactivity (ADHD)
Attention Deficit Disorder (ADD)
Eligibility:
All Genders
6-60 years
Brief Summary
The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.
Detailed Description
This 4-week study will evaluate QbMobile's performance in monitoring ADHD treatment response. Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinica...
Eligibility Criteria
Inclusion
- Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
- Aged \> 6 years and \< 60 years old;
- Referred for an ADHD assessment or has a diagnosis of ADHD but not currently receiving any type of stimulant or nonstimulant medication treatment;
- Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation;
- Qbtech Rating Scale total score of \>24 at Visit 1;
- Have adequate sensory and physical ability to complete QbMobile;
- Possess or has access to an iPhone model that supports QbMobile.
Exclusion
- Intellectual disability designated by IQ\<75);
- Has used psychostimulant medication within 7 days prior to Visit 1;
- A concurrent medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc);
- Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
- Substance use (e.g., alcohol, drugs) that may affect performance on the day of the test.
Key Trial Info
Start Date :
January 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT07217977
Start Date
January 15 2025
End Date
October 1 2026
Last Update
December 31 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Focus-MD
Mobile, Alabama, United States, 36607
2
Prodigy Psychiatric Group
San Jose, California, United States, 95138
3
Bokhari Medical Consortium
Largo, Florida, United States, 33770
4
Nona Pediatric Center
Orlando, Florida, United States, 32829